The Crossover strategy launched in April 2018, completing Sofinnova's investment platform by enabling it to invest across the life-sciences value chain, from seed stage to later-stage.
We invest across all biotech sectors, focusing on companies with game-changing science that has initial proof of concept.
|2018||Sofinnova Crossover I||€445 million|
Fund: Sofinnova Crossover I
AMT: €445 million
"Sometimes you need to have a significant stake in a company and be in the board room to really drive some of the strategy and the changes it may need."
"Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept."
"It is exciting to help companies find that next gear of growth as they bring new medicines to market.”
"The science in Europe is the same quality as any you'll find in the U.S."
MD Start & Crossover
Capital & Crossover
Crossover & Industrial Biotech
Synthace appoints Dr. Donald Deieso as new Board Chair
Abivax announces successful oversubscribed €49.2 million crossover financing with top-tier U.S. and European biotech investors
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
LimFlow raises $40 million (€36 million) in Series D financing